Cardiothoracic CT: one-stop-shop procedure? Impact on the management of acute pulmonary embolism
TL;DR: Two risk stratification models are proposed, combining the markers of RVD with cardiac biomarkers of ischemia to define whether patients should be admitted to the intensive care unit (ICU) and/or be given thrombolysis, admission to the medical ward, or be safely treated at home with anticoagulant therapy.
read more
Abstract: In the treatment of pulmonary embolism (PE) two groups of patients are traditionally identified, namely the hemodynamically stable and instable groups. However, in the large group of normotensive patients with PE, there seems to be a subgroup of patients with an increased risk of an adverse outcome, which might benefit from more aggressive therapy than the current standard therapy with anticoagulants. Risk stratification is a commonly used method to define subgroups of patients with either a high or low risk of an adverse outcome. In this review the clinical parameters and biomarkers of myocardial injury and right ventricular dysfunction (RVD) that have been suggested to play an important role in the risk stratification of PE are described first. Secondly, the use of more direct imaging techniques like echocardiography and CT in the assessment of RVD are discussed, followed by a brief outline of new imaging techniques. Finally, two risk stratification models are proposed, combining the markers of RVD with cardiac biomarkers of ischemia to define whether patients should be admitted to the intensive care unit (ICU) and/or be given thrombolysis, admitted to the medical ward, or be safely treated at home with anticoagulant therapy.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association
Jay Giri,Akhilesh K. Sista,Ido Weinberg,Clive Kearon,Dharam J. Kumbhani,Nimesh D. Desai,Gregory Piazza,Mark T. Gladwin,Saurav Chatterjee,Taisei Kobayashi,Christopher Kabrhel,Geoffrey D. Barnes +11 more
TL;DR: The purpose of this document is to clarify the current state of endovascular interventional therapy for acute PE and to provide considerations for evidence development for new devices that will define which patients with PE would derive the greatest net benefit from their use in various clinical settings.
363
•Journal Article
Computed tomographic pulmonary angiography and prognostic significance in patients with acute pulmonary embolism
Alexandre Ghuysen,Benoît Ghaye,Valérie Willems,Bernard Lambermont,Pierre Gerard,Robert F. Dondelinger,Vincent D'Orio +6 more
TL;DR: In this article, the authors presented a broad spectrum of prognoses for acute pulmonary embolism (APE) patients using computed tomographic pulmonary angiography (CTPA) as a first line test.
172
Interventional Treatment of Pulmonary Embolism
TL;DR: Various hybrid pharmacomechanical approaches have been devised to capture the benefits of thrombolysis while reducing its risks, but there is limited aggregate clinical experience with such novel interventional strategies.
118
Assessment of Right Ventricular Strain by Computed Tomography Versus Echocardiography in Acute Pulmonary Embolism
TL;DR: In acute PE, CT is highly sensitive but only moderately specific for RVS compared to TTE, and TTE confers additional positive prognostic value compared to CT in predicting post-PE clinical deterioration.
58
Endovascular therapies for pulmonary embolism.
Hervé Rousseau,Costantino Del Giudice,Olivier Sanchez,Emile Ferrari,Marc Sapoval,Pierre Marek,Clément Delmas,Charline Zadro,P Revel-Mouroz +8 more
TL;DR: In this paper, the authors define the place of new endovascular methods for the management of pulmonary embolisms (PE), on the basis of a multidisciplinary consensus, based on an appropriate risk stratification of PE.
14
References
Universal definition of myocardial infarction
TL;DR: The past history, and likely future of this important topic has been/will remain more “evolution” than “big-bang”, and the current redefinition was flawed at inception owing to a fundamental problem with the troponin assays available at that time.
Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)
Adam Torbicki,Arnaud Perrier,Stavros Konstantinides,Giancarlo Agnelli,Nazzareno Galiè,Piotr Pruszczyk,Frank M. Bengel,Adrian J B Brady,Daniel Ferreira,Uwe Janssens,Walter Klepetko,Eckhard Mayer,Martine Remy-Jardin,Jean-Pierre Bassand,Alec Vahanian,John Camm,Raffaele De Caterina,Veronica Dean,Kenneth Dickstein,Gerasimos Filippatos,Christian Funck-Brentano,Irene Hellemans,Steen Dalby Kristensen,Keith McGregor,Udo Sechtem,Sigmund Silber,Michal Tendera,Petr Widimsky,José Luis Zamorano,José Luis Zamorano,Felicita Andreotti,Michael Ascherman,George Athanassopoulos,Johan De Sutter,David Fitzmaurice,Tamás Forster,Magda Heras,Guillaume Jondeau,Keld Kjeldsen,Juhani Knuuti,Irene Lang,Mattie J. Lenzen,Jose Lopez-Sendon,Petros Nihoyannopoulos,Leopoldo Pérez de Isla,Udo Schwehr,Lucia Torraca,Jean-Luc Vachiery +47 more
TL;DR: Non-thrombotic PE does not represent a distinct clinical syndrome but may be due to a variety of embolic materials and result in a wide spectrum of clinical presentations, making the diagnosis difficult.
Acute pulmonary embolism: clinical outcomes in the international cooperative pulmonary embolism registry (ICOPER)
TL;DR: Data from ICOPER provide rates and highlight adverse prognostic categories that will help in planning of future trials of high-risk PE patients and highlight significant prognostic factors associated with death.
2.9K
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Clive Kearon,Susan R. Kahn,Giancarlo Agnelli,Samuel Z. Goldhaber,Gary E. Raskob,Anthony J. Comerota +5 more
TL;DR: This chapter about treatment for venous thromboembolic disease is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) and indicates that the benefits do or do not outweigh risks, burden, and costs.
2.1K
Antithrombotic therapy for venous thromboembolic disease.
TL;DR: It is shown that patients with symptomatic proximal DVT may benefit from fitted compression stockings for at least 3 months to reduce the incidence of the postthrombotic syndrome, and patients with VTE who receive adequate anticoagulation generally do not die of recurrent disease.
2.1K
Related Papers (5)
Nils Kucher,Peter Boekstegers,Oliver J. Müller,Christian Kupatt,Jan Beyer-Westendorf,Thomas Heitzer,Ulrich Tebbe,Jan Horstkotte,Ralf Müller,Erwin Blessing,Martin Greif,Philipp S. Lange,Ralf-Thorsten Hoffmann,Sebastian Werth,Achim Barmeyer,Dirk Härtel,Henriette Grünwald,Klaus Empen,Iris Baumgartner +18 more
Gregory Piazza,Benjamin Hohlfelder,Michael R. Jaff,Kenneth Ouriel,Tod C. Engelhardt,Keith M. Sterling,Noah Jones,John C. Gurley,Rohit Bhatheja,Robert J. Kennedy,Nilesh J. Goswami,Kannan Natarajan,John H. Rundback,Immad Sadiq,Stephen K. Liu,Narinder Bhalla,M. Laiq Raja,Barry S. Weinstock,Jacob Cynamon,Fakhir Elmasri,Mark J. Garcia,Mark H. Kumar,Juan Ayerdi,Peter A. Soukas,William T. Kuo,Ping-Yu Liu,Samuel Z. Goldhaber,Seattle Ii Investigators +27 more